Please wait while we open this resource.
K
Clinical reviews
ROLE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN ACHIEVING WEIGHT LOSS AND IMPROVING CARDIOVASCULAR OUTCOMES IN PEOPLE WITH OVERWEIGHT AND OBESITY
Erin D. Michos, MD, MHS; Francisco Lopez-Jimenez, MD, MSc, MBA; Martha Gulati, MD, MS
PDF202314 pages2.5 MB
Obesity is a significant public health issue, linked to increased cardiovascular disease (CVD) risk. This review summarizes various treatment strategies for obesity, including lifestyle changes, bariatric surgery, and pharmacologic interventions. It emphasizes the recent advancements in glucagon-like peptide-1 receptor agonist medications, which have shown promise in aiding weight loss and potentially reducing CVD risk, particularly in patients with type 2 diabetes. The authors advocate for the integration of these therapies into clinical practice for effective obesity management.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
ADA Consensus Report: MASLD in People With Diabetes
Same clinical topic · Endocrinology
2025 ADA Diabetes Care Standards Updates
Same clinical topic · Endocrinology
METFORMIN―MECHANISMS OF ITS GLYCEMIA-REDUCING EFFECT
Same clinical topic · Endocrinology
SYNDROME OF INAPPROPRIATE ANTIDIURESIS: FROM PATHOPHYSIOLOGY TO MANAGEMENT
Same clinical topic · Endocrinology
GLYCEMIC EMERGENCIES
Same clinical topic · Endocrinology
DIAGNOSIS AND MANAGEMENT OF CENTRAL DIABETES INSIPIDUS IN ADULTS
Same clinical topic · Endocrinology
ANTI-OBESITY DRUGS: COMPREHENSIVE REVIEW AND EMERGING THERAPIES
Same clinical topic · Endocrinology
DRUG DELIVERY SYSTEMS FOR THYROID DISEASE TREATMENT: A MINI REVIEW ON CURRENT THERAPIES AND ALTERNATIVE APPROACHES
Same clinical topic · Endocrinology
OTHER BENEFITS OF CONTROLLING CARBOHYDRATES
Same clinical topic · Endocrinology